Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?

Zacks2021-01-22

Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Wapapapow
2021-01-24
Wapapapow
Yes wow
Simmies
2021-01-24
Simmies
Top
Sorrie2u
2021-01-22
Sorrie2u
[龇牙]
- koabi:
  Nice
MustSureHuat
2021-01-22
MustSureHuat
Wow
- 社区成长助手:
  终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2105459536?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-01-22 15:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2105459536","market":"us","top_or_hot":-1,"title":"Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?","media":"Zacks","content":"<html><body><div>\n<p>Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full ...</p>\n<a href=\"https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead\">网页链接</a>\n</div>\n</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead (GILD) Up 19% in the Past Month: What Lies Ahead?\n</h2>\n<h4 class=\"meta\">\n\n\n2021-01-22 15:35 GMT+8   <a href=\"https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead\"><strong>Zacks</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full ...</p>\n<a href=\"https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://www.zacks.com/stock/news/1250053/gilead-gild-up-19-in-the-past-month-what-lies-ahead","article_id":"2105459536","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2105459536","pubTimestamp":1611300933,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and","collect":0,"end_time":0,"defaultTopTitle":"zacks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"Gilead（GILD）在过去一个月上涨了19%:未来如何？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"Shares ofGilead Sciences, Inc. are up 19.3% in the past month. The company, had an eventful 2020 and was in the spotlight due to its coronavirus treatment, Veklury (remdesivir). The FDA granted full approval to Veklury for the treatment of patients with COVID-19 and the European Commission (“EC”) also granted conditional Marketing Authorization for the same.\nThe stock has gained 7.2% in the past year compared with theindustry’s growth of 13.9%.\n\nLast week, the companyincreasedits annual sales guidance for 2020 as the worsening of the coronavirus pandemic drove sales for Veklury. Total product sales are now projected to be $24.3-$24.35 billion for 2020, up from the previous guidance of $23-$23.5 billion. Veklury sales witnessed growth as hospitalization and treatment rates were higher than expected, given the most recent COVID-19 surge. Veklury sales are estimated at $2.8-$2.825 billion.\nTotal product sales, excluding Veklury, are projected to be $21.5-$21.525 billion, considering the underlying strong Biktarvy uptake, partially offset by the loss of exclusivity of Truvada in the United States and the impact of COVID-19 primarily on Gilead’s pre-exposure prophylaxis (“PrEP”) franchise and chronic hepatitis C virus (“HCV”) franchise.\nWhile Veklury sales were strong as the pandemic worsened in the last couple of months, the rollout of vaccines fromPfizer and others might lead to a decline in sales eventually.\nNevertheless, Gilead is likely to maintain momentum on its strong HIV franchise led by Biktarvy despite stiff competition from the likes ofGlaxo. The label expansion of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) as a prevention option has boosted sales of the treatment. The FDA had earlier also extended the indication for Truvada as PrEP to include at-risk adolescents. Approval of new therapies has strengthened the franchise.\nWe remind investors that the massive decline in sales of its once lucrative HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues.\nGilead is diversifying into the oncology space. To that end, it acquired Immunomedics for approximately $21 billion and entered into strategic collaborations to foray into the lucrative oncology space. In April 2020, Gilead acquired Forty Seven for $4.9 billion and gained magrolimab, an investigational monoclonal antibody in clinical development for the treatment of a number of hematological cancers. Gilead also acquired a 49.9% equity interest in Pionyr Immunotherapeutics, Inc., a privately-held company pursuing novel biology in the field of immuno-oncology.\nIt has also collaborated withNovo Nordisk for developing treatments for non-alcoholic steatohepatitis (NASH).\nBiggest Tech Breakthrough in a Generation\nBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.\nA select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":319912782,"gmtCreate":1611471320846,"gmtModify":1703750548235,"author":{"id":"3556787208739110","authorId":"3556787208739110","name":"Wapapapow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3556787208739110","authorIdStr":"3556787208739110"},"htmlText":"Yes wow","listText":"Yes wow","text":"Yes wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/319912782","repostId":2105459536,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":319045782,"gmtCreate":1611453215246,"gmtModify":1703750480965,"author":{"id":"3572983704710838","authorId":"3572983704710838","name":"Simmies","avatar":"https://static.tigerbbs.com/0608b8e0ec6c2954c874d113de5d9eb9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3572983704710838","authorIdStr":"3572983704710838"},"htmlText":"Top","listText":"Top","text":"Top","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/319045782","repostId":2105459536,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":310839659,"gmtCreate":1611301454071,"gmtModify":1703749533278,"author":{"id":"3557997848207595","authorId":"3557997848207595","name":"Sorrie2u","avatar":"https://static.tigerbbs.com/daee3c31c13830f17698139700d5c999","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3557997848207595","authorIdStr":"3557997848207595"},"htmlText":"[龇牙]","listText":"[龇牙]","text":"[龇牙]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/310839659","repostId":2105459536,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3375106,"gmtCreate":1611373769940,"gmtModify":1635768293869,"authorId":3562240188467019,"author":{"id":3562240188467019,"idStr":"3562240188467019","authorId":3562240188467019,"name":"koabi","avatar":"https://static.tigerbbs.com/fbb917db7d1d5438831ae45369d18840","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":310839659,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"CN"},{"id":310897244,"gmtCreate":1611301038188,"gmtModify":1703749529984,"author":{"id":"3565712668199704","authorId":"3565712668199704","name":"MustSureHuat","avatar":"https://static.tigerbbs.com/4f5bd03af999026dd9c0f4255c421c3e","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3565712668199704","authorIdStr":"3565712668199704"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/310897244","repostId":2105459536,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3367695,"gmtCreate":1611301234252,"gmtModify":1611301234252,"authorId":3527667803686145,"author":{"id":3527667803686145,"idStr":"3527667803686145","authorId":3527667803686145,"name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":310897244,"type":1,"supId":0,"prevId":0,"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看<a href=\"https://laohu8.com/TW/934879903\">老虎社区创作指引</a>","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看<a href=\"https://laohu8.com/TW/934879903\">老虎社区创作指引</a>","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看<a href=\"https://laohu8.com/TW/934879903\">老虎社区创作指引</a>"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":4,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.5","shortVersion":"4.31.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2105459536"}